Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Deferred Taxes (2016 - 2021)

Historic Deferred Taxes for ImmunityBio (IBRX) over the last 7 years, with Q4 2021 value amounting to -$8000.0.

  • ImmunityBio's Deferred Taxes rose 9613.53% to -$8000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was -$8000.0, marking a year-over-year increase of 9972.77%. This contributed to the annual value of -$4000.0 for FY2022, which is 5000.0% up from last year.
  • According to the latest figures from Q4 2021, ImmunityBio's Deferred Taxes is -$8000.0, which was up 9613.53% from -$207000.0 recorded in Q4 2020.
  • ImmunityBio's Deferred Taxes' 5-year high stood at $38000.0 during Q2 2020, with a 5-year trough of -$1.7 million in Q3 2020.
  • Its 5-year average for Deferred Taxes is -$282071.4, with a median of -$124000.0 in 2017.
  • Per our database at Business Quant, ImmunityBio's Deferred Taxes plummeted by 248750.0% in 2020 and then skyrocketed by 9613.53% in 2021.
  • ImmunityBio's Deferred Taxes (Quarter) stood at -$182000.0 in 2017, then soared by 32.97% to -$122000.0 in 2018, then surged by 93.44% to -$8000.0 in 2019, then plummeted by 2487.5% to -$207000.0 in 2020, then surged by 96.14% to -$8000.0 in 2021.
  • Its Deferred Taxes was -$8000.0 in Q4 2021, compared to -$207000.0 in Q4 2020 and -$1.7 million in Q3 2020.